MYC and acute myeloid leukemia: ML-792, the “precursor” of TAK-981, had been tested as a potential SUMO inhibitor based on its ability to inhibit proliferation in AML cell lines, especially in those overexpressing the Myc oncogene; however, it led to chromosome-segregation defects, further resulting in proliferation arrest and death of both AML cells and normal hematopoietic cells [124].